Cellular therapies have emerged as an effective new therapy for patients with certain types of cancer, and MD Anderson has played an important role in advancing these novel treatments to the clinic. With recent agreements, MD Anderson has expanded its manufacturing and research capacity for cell therapies to bring new treatment options to more patients.
This month, MD Anderson finalized an asset purchase agreement with Bellicum...
An international consortium, led in part by clinicians and researchers from The University of Texas MD Anderson Cancer Center, has published...
The Therapeutics Discovery division at MD Anderson Cancer Center has advanced a new small-molecule inhibitor of cancer metabolism to Phase...
Through in-depth retrospective analysis of data from more than 36,000 patients, a new study led by researchers at The University of Texas MD Anderson Cancer Center found that early-onset colorectal cancer (CRC) has distinct clinical and molecular features compared to those diagnosed later in life. Their findings were published recently in the journal CANCER.
The researchers discovered that patients with early-onset CRC, those diagnosed...
Neoadjuvant therapy is treatment, such as chemotherapy or radiation, given before a patient has surgery. This approach is used in many cancer...
MD Anderson’s proteomics platform provides a valuable institutional resource, complete with state-of-the-art instruments and specialized expertise...
Chronic lymphocytic leukemia (CLL), which originates in white blood cells known as lymphocytes, is the most common form of leukemia in adults...
MD Anderson Cancer Center researchers, together with collaborators from Mozambique, Brazil and the U.S., have been awarded a $5.1 million...
Receiving a cancer diagnosis is a life-changing event, and the path through treatment can be among the hardest things a person goes through...
Lymphomas are the most common hematological malignancy in the U.S., accounting for an estimated 80,000 new cancer diagnoses and 21,000 deaths...